Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer

bioRxiv (Cold Spring Harbor Laboratory)(2019)10.1101/605436Source: DataRank Database

Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2019). On theSindex it has a DataRank of 0.269. It has been cited 5 times.

N/A

0.269DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)OA: greenTopics (39)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.269

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (20)

Ofir Cohen ORCID,Kailey J. Kowalski,Justin G. Kusiel,Jorge E. Buendia-Buendia ORCID,Michael S. Cuoco ORCID

Live enrichment

PubMed:26657633 OpenAlex:https://openalex.org/W2940326670

National Institutes of Health

Grant: 5P50CA168504-03

Overcoming Resistance to Standard HER2-Directed Therapies for Breast Cancer

green

repositoryhttps://www.biorxiv.org/content/biorxiv/early/2019/10/07/605436.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1101/605436

repositoryhttps://doi.org/10.1101/605436

https://doi.org/10.1158/1078-0432.ccr-19-3958

Fields of Study

Fibroblast Growth Factor ResearchCancer Genomics and DiagnosticsCancer Cells and Metastasis0301 basic medicine03 medical and health sciences

Keywords

FulvestrantCancer researchBreast cancerPalbociclibEstrogen receptorFibroblast growth factor receptorCancerBiologyErbBEstrogen receptor alphaMetastatic breast cancerMedicineInternal medicineFibroblast growth factorReceptorAdultPyridinesFibroblast Growth Factor 3Breast NeoplasmsMiddle AgedPiperazinesGene Expression Regulation, NeoplasticReceptors, EstrogenDrug Resistance, NeoplasmCell Line, TumorMutationMCF-7 CellsHumansFemaleReceptor, Fibroblast Growth Factor, Type 1Neoplasm MetastasisReceptor, Fibroblast Growth Factor, Type 2Protein Kinase InhibitorsAged

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being